In multivariate analysis including age, sex, tumor type, stage, newly diagnosed versus recurrent disease and treatment modalities, the hazard ratio for VTE in cancer patients with FVL mutation was 2.0 (95% CI, 1.0–4.0). The gene discussed is F5; the disease is cancer.